Should per se limits be imposed for cannabis? Equating cannabinoid blood concentrations with actual driver impairment: Practical limitations and concerns

Humboldt Journal of Social Relations

Volumn 35, Issue 1, 2013, Pages 41-51

  Armentano, Paul ^a  

^a National Organization for the Reform of Marijuana Laws   (United States)

Author keywords

Cannabinoids; Cannabis; Carboxy THC; Driving; Impairment; Marijuana; Medical marijuana; Per se; Psychomotor skills; THC

Indexed keywords

EID: 84900814062     PISSN: 01604341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Armentano, P. (2013). Cannabis and psychomotor performance: A rational review of the evidence and implications for public policy. Drug Testing and Analysis, 5, 52-56.
2. Asbridge, M, Hayden JA, Cartwright JL. (2012). Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. British Medical Journal 344:e536.
3. Associated Press. (March 18, 2012). Stoned driving epidemic puts wrinkle in marijuana debate.
4. Chesher G., Longo M. (2002). Cannabis and Alcohol in Motor Vehicle Accidents. In Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential, (Eds: Grotenhermen, F, Russo, E.). Haworth Integrative Healing Press, New York, pp. 313-323.
5. Drummer, OH, Gerostamoulos, J, Batziris, H, Chu, M, Caplehorn, J, Robertson, MD, Swann, P. (2004). The involvement of drugs in drivers killed in Australian road traffic crashes. Accident Analysis & Prevention, 36:239-48.
6. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Copper T, Perry E, Krystal J. (2008). Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33:2505-16.
7. Elvik R. (2012). Risk of road accident associated with the use of drugs: A systematic review and meta-analysis of evidence from epidemiological studies. Accident Analysis and Prevention, doi.org/10.1016/j.aap.2012.06.017.
8. Executive Office of the President of the United States. National Drug Control Strategy, 2012. Washington, DC. 2012.
9. Fischer B, Jeffries V, Hall W, Room R, Goldner E, Rehm J (2011). Lower risk cannabis use guidelines for Canada: A narrative review of evidence and recommendations. Canadian Journal of Public Health, 102:324-7.
10. Grant I, Atkinson JH, Gouaux B, Wilsey B (2012). Medical marijuana: clearing away the smoke. The Open Neurology Journal, 6:18-25.
11. Grotenhermen F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmocokinetics, 42:327-60.
12. Grotenhermen F, Leson G, Berhaus G, Drummer OH, Kruger HP, Longo M, Moskowitz H, Perrine B, Ramaekers JG, Smiley A, Turnbridge R (2005). Developing Science-Based Per Se Limits for Driving Under the Influence of Cannabis (DUIC): Findings and Recommendations by an Expert Panel. Marijuana Policy Project, Washington, DC.
13. Grotenhermen F, Leson G, Berhaus G, Drummer OH, Kruger HP, Longo M, Moskowitz H, Perrine B, Ramaekers JG, Smiley A, Turnbridge R (2007). Developing per se limits for driving under cannabis. Addiction, 102:1910-7.
14. Grotenhermen F, Muller-Vahl K (2012). The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt International, 109:29-30.
15. Hart CL, Ilan EB, Gevins A, Gunderson EW, Role K, Colley J, Foltin RW (2010). Neurophysiological and cognitive effects of marijuana in frequent users. Pharmacology Biochemistry and Behavior, 96:333-41.
16. Huestis MA, Henningfield JE, Cone EJ (1992). Blood cannabinoids. 1. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. Journal of Analytical Toxicology, 16:276-82.
17. Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Pope HG, Herning R, Cadet JL, Huestis MA (2009). Do Delta-9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction, 104:2041-48.
18. Khiabani HZ, Bramness JG, Bjorneboe A, Morland J (2006). Relationship between THC concentration in blood and impairment in apprehended drivers. Traffic Injury and Prevention, 7:111-6.
19. Laumon B, Gadegbeku B, Martin JL, Biecheler, MB, SAM Group (2005). Cannabis intoxication and fatal road crashes in France: a population base case-control study. British Medical Journal, 331:1371-77.
20. Musshoff F, Madea B (2006). Review of biological matrices (urine, blood, and hair) as indicators of recent or ongoing cannabis use. Therapeutic Drug Monitoring, 28:155-63.
21. National Highway Traffic Safety Administration. (1993). Marijuana and Actual Driving Performance. Washington, DC.
22. National Highway Traffic Safety Administration. (1999). Drug Evaluation and Classification Training "The Drug Recognition Expert School" Student Manual. Washington, DC..
23. National Highway Traffic Safety Administration. (2003). State of Knowledge of Drug-Impaired Driving: Final Report. Department of Transportation report HS 809 642. Washington, DC..
24. National Highway Traffic Safety Administration. (n. d.). Drugs and Human Performance Fact Sheets: Cannabis/Marijuana (Delta-9-tetrahydrocannabinol) Webpage accessed on September 3, 2012.
25. National Organization for the Reform of Marijuana Laws (NORML). (n. d.). Active State Medical Marijuana Programs Webpage accessed on January 13, 2013.
26. National Organization for the Reform of Marijuana Laws (NORML). (n. d.). State DUID Laws Webpage accessed on January 13, 2013.
27. Paula K, Kuypers C, Legrand SA, Ramaekers JG, Verstraete AG (2012). A case-control study estimating accident risk for alcohol, medicines, and illegal drugs. PLoS ONE, 7(8):e43496
28. Ramaekers JG, Berghaus G, Van Laar M, Drummer OH (2004). Dose related risk of motor vehicle crashes after cannabis use. Drug and Alcohol Dependence, 7:109-19.
29. Ramaekers JG (2006) "Commentary of Cannabis and Crash Risk: Concentration Effect Relations." In Transportation Research Circular: Number E-C096 (Eds Transportation Research Board of the National Academies) Woods Hole, Massachusetts, pp. 65-66.
30. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology, 23:266-77.
31. Ramaekers JG, Berhaus G, Van Laar MW, Drummer OH (2010). "Dose related risk of motor vehicle crashes after cannabis use: an update." in Drugs, Driving, and Traffic Safety (Eds: J. C. Verster, D. R. Pandi-Perumai, J. G. Raemakers, J. J. de Gier) Birkhauser, Basel, Switzerland, pp: 501-518.
32. Ramaekers JG, Theunissen EL, De Bower M, Toennes SW, Moeller MR, Kauert G (2010) Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology (Berl), 214:391-401.
33. Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, Cassuto Y, Shinar D (2008). Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accident Analysis and Prevention, 40:926-934.
34. Schwope DM, Bosker WM, Ramaekers JG, Goerlick DA, Huestis, MA (2012). Psychomotor performance, subjective and physiological effects of whole blood delta-9-THC concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. Journal of Analytical Toxicology, 36:405-12.
35. Sewell RA, Polling J, Sofuoglu M (2009). The effect of cannabis compared to alcohol on driving. American Journal on Addictions, 18:185-93.
36. Silver, N (October 18, 2011). "Gallup poll is first to find plurality support for marijuana legalization. " The New York Times.
37. Skopp G, Potsch L (2008). Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking. Journal of Analytical Toxicology, 32:160-4.
38. Stough, C., Boorman, M., Odgen, E., Papafotiou, K. An Evaluation of the Standardised Field Sobriety Test for the Detection of Impairment Associated With Cannabis With and Without Alcohol. Australian Government Department of Health and Aging, Canberra, 2006.
39. Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF (2008). Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. Journal of Analytical Toxicology, 32:470-77.